<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To characterize patients with mixed myeloid <z:hpo ids='HP_0002664'>neoplasias</z:hpo> with proliferation of neutrophils, platelets and eosinophils </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: Examination and treatment results were analysed for patients with atypical myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 4), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, n = 1) and <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> (n = 1) </plain></SENT>
<SENT sid="2" pm="."><plain>The examination included morphological, histological, cytogenetic and molecular tests </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: One patient with atypical <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> was prior diagnosed to have primarily <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with a typical aberration of chromosome 5 </plain></SENT>
<SENT sid="4" pm="."><plain>Two other patients had an initial morphological picture of resistant <z:hpo ids='HP_0001903'>anemia</z:hpo> with blast excess, signs of myeloproliferation and <z:mp ids='MP_0000240'>extramedullary hemopoiesis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>One and two months after the first examination they received transfusions of erythrocytic mass </plain></SENT>
<SENT sid="6" pm="."><plain>Just then they were found to have <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> and <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> due to proliferating and maturating forms of neutrophils </plain></SENT>
<SENT sid="7" pm="."><plain>The course of the disease in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype and in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> and combined chromosomal breaks including translocation (3;12)(q21;p13) was characterized by resistance to standard programs of polychemotherapy and transformation into <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: In some cases atypical <z:mp ids='MP_0005481'>CML</z:mp> is a stage of a natural course of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> variants with <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> and <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> should be referred to the group of mixed myeloid <z:hpo ids='HP_0002664'>neoplasias</z:hpo> </plain></SENT>
</text></document>